Researchers from the Spanish National Cancer Research Centre (CNIO) deciphered one of the molecular pathways behind lung cancer and used this information to identify an experimental drug, which blocks lung cancer growth in mice.
The team has identified the molecular pathways by which a gene Notch, involved in development of some cancers regulates cell proliferation in lung cancer.
"We have found that this protein cooperates with the Ras oncogene, a key element in the formation of these tumours," Manuel Serrano, lead researcher said in a statement.
They also discovered the therapeutic effect of a specific experimental drug which blocks Notch efficiently, named GSIs (Gamma-Secretase Inhibitors).
GSIs were developed over 15 years ago to treat Alzheimer's disease.
The study used genetically modified mice previously developed by Mariano Barbacid, head of the Experimental Oncoloy Group at the CNIO, that faithfully recapitulate human lung cancer.
"After 15 days of treatment, lung tumours failed to grow without treatment-related side effects," Antonio Maraver, the first author of the study, said.
The study was published in the journal Cancer Cell.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
